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Abstract: In recent years, percutaneous coronary intervention (PCI) has become a well-established technique for the 
treatment of coronary artery disease. PCI improves symptoms in patients with coronary artery disease and it has been in-
creasing safety of procedures. However, peri- and post-procedural myocardial injury, including angiographical slow coro-
nary flow, microvascular embolization, and elevated levels of cardiac enzyme, such as creatine kinase and troponin-T and 
-I, has also been reported even in elective cases. Furthermore, myocardial reperfusion injury at the beginning of myocar-
dial reperfusion, which causes tissue damage and cardiac dysfunction, may occur in cases of acute coronary syndrome. 
Because patients with myocardial injury is related to larger myocardial infarction and have a worse long-term prognosis 
than those without myocardial injury, it is important to prevent myocardial injury during and/or after PCI in patients with 
coronary artery disease. To date, many studies have demonstrated that adjunctive pharmacological treatment suppresses 
myocardial injury and increases coronary blood flow during PCI procedures. In this review, we highlight the usefulness of 
pharmacological treatment in combination with PCI in attenuating myocardial injury in patients with coronary artery dis-
ease. 
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INTRODUCTION 
  Percutaneous coronary intervention (PCI) relieves car-
diac ischemia, resulting in improvement of symptoms in 
patients with coronary artery disease (CAD). Although PCI 
has been widely performed in the management of CAD, non-
Q wave myocardial infarction (MI) can occur in 10-40% of 
patients after elective PCI [1-5]. This phenomenon can be 
detected by changes of electrocardiography (ECG) and ele-
vation of cardiac enzymes such as troponin-I and T, creatine 
kinase (CK), creatine kinase-myocardial band isoenzyme 
fraction (CK-MB), and so on. There are many reports that 
myocardial damage during PCI is associated with increase in 
risk of major in-hospital complications and major adverse 
clinical events, even if it is small [5-11]. In many cases, car-
diac enzyme elevation results from various procedural events 
including side branch closure and distal thromboembolism, 
which can be confirmed by coronary angiography [12]. 
However, in some cases, cardiac enzyme elevations occur 
even without discernible complications. Dilatation of plaque 
and vessel wall, which include lipid, matrix, endothelial cells 
and platelet thrombus, may induce microcirculatory embo-
lism after angioplasty [13,14]. Therefore, coronary dilation 
and reduction of oxidative stress, inflammation, and platelet 
activation triggered by medications may thus attenuate minor 
cardiac necrosis during and after PCI, and reduce cardiac 
enzyme marker release. Recently, coronary stent implanta-
tion, which features a lower rate of restenosis during follow-
up period than balloon angioplasty alone, has becomes a 
popular procedure [15,16]. However, it is associated with a 
higher incidence of cardiac enzyme elevation than balloon  
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angioplasty, and use of intracoronary metallic stent increases 
platelet activation [17,18]. Therefore, preventing cardiac 
enzymate elevations is now becoming of much greater im-
portance. 
  In patients with acute coronary syndrome, including un-
stable angina and acute myocardial infarction (AMI), myo-
cardial reperfusion injury at the beginning of myocardial 
reperfusion may occur, resulting in myocardial tissue dam-
age and cardiac dysfunction. In such situations, ECG, myo-
cardial contrast echocardiographical and angiographical find-
ings after successful PCI can detect myocardial reperfusion 
at the microcirculatory level and myocardial damage [19-
22]. 
  Combined use of pharmacological intervention in addi-
tion to PCI may moderate microcirculatory impairment and 
eventually reduce the incidence and/or severity of infarction, 
resulting in better clinical outcomes after PCI. In this review, 
the usefulness of pharmacological treatment in combination 
with PCI in attenuating myocardial injury in patients with 
CAD is highlighted.
GLYCOPROTEIN IIb/IIIa INHIBITORS 
  The platelet surface glycoprotein IIb/IIIa receptors play 
an important role in the final common pathway leading to 
platelet aggregation [23,24]. Platelet deposition and aggrega-
tion are activated during PCI, particularly coronary stent 
implantation [13,14,25]. This phenomenon may induce plate-
let aggregation, which is related to acute coronary closure 
after procedures. Glycoprotein IIb/IIIa inhibitors disperse 
platelet deposition and also protect coronary microcircula-
tion from embolization of platelet thrombi, which is some-
times induced by coronary balloon inflation and stent im-
plantation. Therefore glycoprotein IIb/IIIa inhibitors have 
beneficial effects on preventing myocardial injury in these 
contexts.  224 Current Cardiology Reviews, 2008, Vol. 4, No. 3 Ishii et al. 
  In many large trials, some glycoprotein IIb/IIIa inhibitors 
have been reported to be effective in reducing ischemic 
complications in patients treated with PCI [24-30]. Of vari-
ous glycoprotein IIb/IIIa inhibitors, abciximab has been most 
often used in trials for evaluation of clinical outcomes in 
patients undergoing PCI. In the EPIC trial, abciximab re-
duced the incidence of acute ischemic events by 35% in pa-
tients undergoing PCI [26]. However, it increased the inci-
dence of major bleeding complications. In that study, con-
current administration of high doses of heparin was used. In 
the EPILOG trial [27], abciximab also had beneficial effects 
in reducing the risk of acute ischemic complications after 
PCI procedures. In bleeding complications, there were no 
significant differences among the group assigned to placebo 
with standard-dose heparin, the group assigned abciximab 
with low-dose, weight-adjusted heparin, and the group as-
signed abciximab with standard-dose, weight-adjusted hepa-
rin, though minor bleeding events were more frequently seen 
in the group assigned abciximab with standard-dose heparin. 
In a sub-analysis of the EPISTENT trial [29], abciximab 
significantly reduced angiographic complications including 
major and minor dissections, distal embolization, thrombus 
postprocedure, side branch or other vessel occlusion, residual 
stenosis >50%, transient coronary occlusion, and Throm-
bolysis In Myocardial Infarction (TIMI) final flow <3 during 
coronary stenting, compared with placebo [30]. In that study, 
abciximab also significantly reduced the incidence of CK-
MB elevation in patients without angiographic complica-
tions.  
  According to AMI patients undergoing PCI, it has been 
reported that administration of glycoprotein IIb/IIIa inhibi-
tors improves myocardial reperfusion [31,32]. In the ADMI-
RAL trial [31], early administration of abciximab (a 0.25 
mg/kg abciximab bolus before catheterization followed by a 
12-hour infusion of 0.125 Eg/kg/min) significantly improved 
coronary patency before and after stenting in patients with 
AMI, compared to placebo administration. A meta-analysis 
of six randomized trials showed that early administration of 
glycoprotein IIb/IIIa inhibitors in patients with ST-elevation-
AMI improved coronary patency after PCI with favorable 
trends for clinical outcomes [32]. 
Bivalirudin 
  Bivalirudin is a direct thrombin inhibitor. Some studies 
found that bivalirudin use to be noninferior to treatment with 
heparin plus glycoprotein IIb/IIIa inhibitors [33,34]. Fur-
thermore, bleeding complications were less frequently seen 
in patients with periprocedural bivalirudin therapy than in 
patients with heparin plus glycoprotein IIb/IIIa inhibitors 
[34]. Thus, in this context, bivalirudin has a beneficial effect. 
Thienopyridine  
  Thienopyridine compounds such as ticlopidine and 
clopidogrel inhibit the platelet adenosine diphosphate recep-
tor, resulting in blocking platelet aggregation. Dual antiplate-
let therapy with aspirin and thienopyridine compound is 
widely used to prevent stent thrombosis and ischemic com-
plication after PCI procedure [35, 36]. However, there are 
few studies focusing on the effect of pre-treatment with 
thienopyridine on preventing procedural related myocardial 
injury in patients undergoing PCI.  
  One retrospective report suggests that beginning ti-
clopidine therapy several days prior to elective stent implan-
tation was associated with a reduced risk of procedural non-
Q-wave myocardial infarction [37]. On the other hand, a 
prospective study reported that pretreatment with clopidogrel 
failed to decrease post-procedural elevation of troponin I and 
CK-MB [38]. It is also controversial whether there is an ad-
ditive anti-platelet effect of ticlopidine in combination with 
glycoprotein IIb/IIIa inhibitors. 
Adenosine  
  It is well known that brief episodes of ischemia in pa-
tients with repetitive balloon inflation during elective PCI 
relieve angina attack and ST elevation in ECG and that ef-
fects of transient episodes of angina protect myocardium 
from ischemic damage in patients with acute coronary syn-
drome [39-45]. These cardioprotective effects are called pre-
conditioning phenomenon. Adenosine plays a key role in 
preconditioning of myocardium [46,47], and thus might 
therefore have a beneficial effect in preventing myocardial 
necrosis following PCI, in addition to its vasodilator effect.  
  A small clinical trial consisting of 28 patients (16 in the 
control group and 12 in the adenosine group) showed that the 
intracoronary administration of adenosine (1 mg/min in the 
right coronary artery or 2 mg/min in the left coronary artery) 
over a 10-minute period during PCI reduced release of serum 
CK-MB 24 hours after PCI [48].  
 Hanna  et al. reported that intracoronary administration of 
adenosine prevented no reflow phenomenon during rota-
tional atherectomy [49]. This report is very important be-
cause that slow flow and no reflow phenomenon is a com-
mon complication of rotational atherectomy [50,51].  
  It has been reported that in AMI patients treated with 
PCI, intracoronary administration of 4 mg adenosine in 2 ml 
saline into the distal bed of a totally occluded vessel pre-
vented no-reflow phenomenon, and improved LV function a 
week after PCI [52]. 
Nitric Oxide  
  Nitric oxide has been used for the relief of attacks of an-
gina. Nitrates improve the myocardial oxygen supply-to-
demand ratio in ischemic zones and relax coronary smooth 
muscle cells, resulting in suppression of coronary vaso-
spasms [53-55]. 
 Kurz  et al. examined whether the intravenous administra-
tion of nitroglycerin for 12 hours after elective coronary 
stenting would decrease the incidence of angina and minor 
myocardial necrosis, as detected by cardiac troponin I in-
crease, in a prospective, single center study including 100 
patients [56]. Although the incidence of post-procedural 
chest pain did not differ between the two groups, the rate of 
occurrence of minor myocardial necrosis was significantly 
reduced in the nitroglycerin group.  
 Amit  et al. reported that the intracoronary administration 
of nitroprusside (60 Eg), selectively injected into distal to the 
occlusion of the infarct-related artery, did not prevent the no-
reflow phenomenon in patients with AMI, treated with pri-
mary PCI, although nitroprusside improved clinical out-
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Table 1.  Adjunctive Pharmacological Therapy in Combination with Percutaneous Coronary Intervention  
Cardioprotective  
Strategy and Trial 
No. of Patients  Detail of Study  Findings 
Glycoprotein IIb/IIIa inhibitors 
 EPIC [26]  2099  A bolus and an infusionof placebo, a bolus
of abciximab and an infusion of placebo,or
a bolus and an infusion of abciximab in 
patients undergoing high-risk percutaneous
coronary revascularizationprocedures 
As compared with placebo, the abciximab bolus and infusion
resulted in a 35 percent reduction in the rate of the adverse 
cardiac events (12.8% vs. 8.3%, p = 0.008), whereas a 10 
percentreduction was observed with the abciximab bolus 
alone (12.8% vs.11.5%, p = 0.43). 
 EPILOG [27]  2792  Standard-dose,weight-adjusted heparin 
(initial bolus of 100 U per kilogramof 
body weight); abciximab with low-dose, 
weight-adjusted heparin(initial bolus of 70
U per kilogram); or placebo with standard-
dose,weight-adjusted heparin in patients 
undergoing urgent or elective PCI  
Abciximab treatment, together with weight-adjustedheparin,
markedly reduces the risk of acute ischemic complicationsin
patients undergoing PCI. Although there were no significant 
differencesamong the groups in the risk of major bleeding, 
minorbleeding was more frequent among patients receiving 
abciximabwith standard-dose heparin. 
 EPISTENT [30]  1587  Treatment with abciximab (0·25 mg/kg 
before intervention, followed by an infu-
sion of 0·125 Jg/kg/min for 12 h) or pla-
cebo in patients undergoing stent implanta-
tion. 
Abciximab (compared with placebo) significantly reduced 
the incidence of CK-MB elevation >3 times normal in those 
without any angiographic complications (6.5% vs. 10.7%; p 
= 0.007). 
 ADMIRAL [31]   300  Abciximab (a bolus of 0·25 mg/kg before 
intervention, followed by a 12-hour infu-
sion of 0·125 Jg/kg/min) or placebo in 
patients with AMI 
Treatment with abciximab significantly improved coronary 
patency before and after stenting in patients with AMI, com-
pared to placebo administration (16.8% vs. 5.4%, p = 0.01 
and 95.1% vs. 86.7%, p = 0.04, respectively).  
Bivalirudin 
 Feldman, DN et al. [34] 2504 Bivalirudin (a 0.75-mg/kg intravenous 
bolus followed by an infusion of 1.75 
mg/kg per hour for the duration of the PCI 
procedure) or abciximab (a 0.25-mg/kg 
bolus and a 0.125 Jg/kg /min infusion for 
12 hours) in patients undergoing PCI with 
drug-eluting stents 
The incidence of cardiac adverse events was similar in the 
bivalirudin and heparin plus GP IIb/IIIa inhibitor groups. 
There was a lower incidence of major (0.7% vs 1.9%, P = 
.012) and minor bleeding (9.6% vs 15.6%, P < .001) in the 
bivalirudin versus heparin plus GP IIb/IIIa inhibitor group. 
Thienopyridine 
 Steinhubl, SR et al. [37] 175 Ticlopidine pretreatment: >3 days before 
theprocedure, 1 to 2 days, or <1 day before
stent implantation 
Ticlopidine pretreatment of > 3 days was associated with a 
significantreduction in the risk of non–Q-wave MI (unad-
justed oddsratio 0.18, 95% confidence interval = 0.04 to 
0.78, p = 0.01)compared with pretreatment of <3 days. 
Adenosine 
 ADELINE pilot trial 
[48] 
28 Intracoronary 1 mg/min in the right coro-
nary artery or 2 mg/min in the left coro-
nary artery over a 10 minute period or 
placebo in patients undergoing elective 
PCI 
There was a significant difference in CK-MB increase from 
baseline to 24 hours after the PCI between the adenosine 
treated and the control group (1.15 vs. 7.36 Jg/l, p = 0.047). 
 Marzilli, M et al. [52]  54  Intracoronary adenosine (4 mg) or saline in
AMI patients undergoingprimary PCI 
The no-reflowphenomenon was seen in 1 adenosine patient 
and in 7 saline patients (p = 0.02).A Q-waveMI developed 
in 59.3% of the adenosine group and in 85.2% of the saline 
group (p = 0.04). 
Nitric oxide 
 Kurz, DJ et al. [56]  100  Intravenous nitroglycerin or placebo dur-
ing 12 hours after stenting in patients with 
stable or unstable angina 
The occurrence of minor myocardial necrosis was 5% in the 
nitroglycerin group and 22% in the placebo group (p = 
0.036).  226 Current Cardiology Reviews, 2008, Vol. 4, No. 3 Ishii et al. 
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Cardioprotective  
Strategy and Trial 
No. of Patients  Detail of Study  Findings 
Amit, G et al. [57]  98  Nitroprusside (60 Fg) selectively injected 
into the infarct-related artery, distal to the 
occlusion or placebo in ST-elevation AMI 
patients 
Selective intracoronary administration of nitroprusside failed
to improve myocardial perfusion, assessed by angiography or
ECG. However, nitroprusside improved clinical outcomes at 
6 months after PCI.  
Nicorandil 
 Murakami, M et al. [63] 192 Intravenous nicorandil (2 Fg/kg/min ad-
ministered just before PCI and continued 
for 6 hours) or control in patients undergo-
ing elective coronary stenting 
The incidence of CK-MB elevation after PCI was signifi-
cantly lower in patients treated with nicorandil than in those 
without nicorandil (8.8% vs. 21.8%, p <0.05). The mean 
peak CK-MB level postprocedure was 13.4 IU in patients 
with nicorandil and 16.5 IU in those without nicorandil (p 
<0.01). 
 Kuwabara, Y et al. [64]  48  Intracoronary and intravenous nicorandil 
during PCI or control in patients undergo-
ing elective PCI  
Nicorandil improved the recovery of myocardial fatty acid 
utilization and cardiac function after PCI, quantitatively 
evaluated by means of iodine-123-beta-methyl-p-iodophenyl-
pentadecanoic acid single photon emission computed tomo-
graphy. 
 Ito, H et al. [66]  81  Intravenous nicorandil (6 mg for 24 hours 
after bolus injection at a dose of 4 mg) or 
control in patients with anterior AMI 
The frequency of no reflow phenomenon detected by myo-
cardial contrast echocardiography was significantly lower in 
the nicorandil group than in the control group (15% vs. 33%,
p < 0.05). 
 Ishii, H et al. [67]  368  Intravenous 12 mg dose of nicorandil or 
placebo in patients with ST elevation AMI 
Postprocedural TIMI 3 flow was obtained in 89.7% of the 
nicorandil group and in 81.4% of the placebo (hazard ratio 
1.99, 95% CI 1.09-3.65; p = 0.025). Corrected TIMI frame 
count was 21.0 ± 9.1 in the nicorandil group and 25.1 ± 14.1 
in the placebo group (p = 0.0009). ST-segment resolution 
>50% was observed in 79.5% of the nicorandil group and in 
61.2% of the placebo group (hazard ratio 2.45, 95% CI 1.54-
3.90; p = 0.0002). 
Beta-blocker 
 Sharma, SK et al. [73]  1675  Beta-blocker administration before PCI or 
no beta-blocker administration 
The incidence of CK-MB elevation after PCI was signifi-
cantly lower in patients on beta-blocker than in those without
beta-blockers (13.2% vs. 22.1%, p <0.001). The mean peak 
CK-MB level postprocedure was 29 IU in patients on beta-
blocker and 38 IU in those without beta-blockers (p <0.002).
Ellis, SG et al. [74]  6200  Beta-blocker administration before PCI or 
no beta-blocker administration  
There was no difference in either maximum CK rise or 
maximum CK-MB rise after PCI between patients with and 
without beta-blocker after adjustment for significant differ-
ences in baseline characteristics. 
 Wang, FW et al. [75]  150  Propranolol (15 Fg/kg) injected into the 
coronary artery through the dilatation 
catheter with the tip distal to the coronary 
lesion or placebo  
The incidence of CK-MB elevation after PCI was seen in 
17% of patients treated with propranolol and 36% of patients
with placebo (p = 0.01). Patients in the propranolol group 
had lower incidence of troponin T elevation than patients in 
the placebo group (13% vs. 33%, p = 0.005). 
Angiotensin converting enzyme inhibitor 
 Leesar, MA et al. [79]  22  Intracoronary 0.75 mg dose of enalaprilat 
or placebo in patients with chronic stable 
angina 
In the placebo group, the ST-segment shift was greater dur-
ing the first balloon inflation than during the second and third
inflations, both on the intracoronary ECG (21.0 ± 2.8 mm vs.
13.0 ± 2.0 mm and 13.0 ± 2.0 mm, p < 0.05) and on the 
surface ECG (16.0 ± 4.0 mm vs. 10.0 ± 2.0 mm and 9.0 ± 2.0
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Cardioprotective  
Strategy and Trial 
No. of Patients  Detail of Study  Findings 
Statin 
ARMYDA [86]  153 Atorvastatin (40 mg/day) or placebo 7 days
before elective PCI for chronic stable 
angina 
The incidence of myocardial infarction by CK-MB determi-
nation was significantly lower in the atrvastatin group than in
the placebo group (5% vs. 18%, p = 0.025). 
Briguori, C et al. [87]  451  Statin administration at least 3 days before
elective PCI or no statin administration 
Median CK-MB peak after PCI was significantly lower in the
statin group than in the control group (1.70 vs. 2.20 ng/ml, p 
= 0.015). The incidence of a large non-Q-wave myocardial 
infarction was also lower in the statin group (8.0% vs. 
15.6%: odds ratio 0.47; 95% confidence interval = 0.26-0.86,
p = 0.012). 
Ishii, H et al. [88]  386  Chronic statin therapy for 1 month before
the onset of a first AMI or control 
Patients in the statin group had a significantly lower maxi-
mum CK level (2300 vs. 3538 IU/ml, p = 0.015) and a lower
corrected TIMI frame count (18.8 vs. 24.2, p = 0.017) than 
patients in the non-statin group. 
Iwakura, K et al. [89]  293  Chronic statin treatment before admission 
for AMI or control 
Patients in the statin group had lower incidence of the no-
reflow detected by intracoronary myocardial contrast echo-
cardiography than patients in the control (9.1% vs. 34.6%, p 
= 0.003). 
Nicorandil  
  Pharmacological treatment with ATP-sensitive potassium 
channel openers have similar cardioprotective effects like 
ischemic preconditioning [45,58]. As mentioned above, 
ischemic preconditioning effects can help avoid complica-
tions during PCI and have important therapeutic implica-
tions. 
  Nicorandil, a hybrid of adenosine triphosphate-sensitive 
K channel opener and nitrates, has vasodilatory effects and 
thus increases coronary blood flow particularly in small ves-
sels, prevents vasospasms and improves microvascular circu-
lation [58-61], and cardiac sympathetic nerve activity, and 
thereby prevents slow flow in patients with ischemic heart 
disease [62]. For these reasons, nicorandil is now used as a 
pharmacological adjunct to PCI. Murakami et al. investi-
gated whether intravenous 6-hour nicorandil infusion (a dose 
of 2 Dg/kg/min starting just before PCI) would reduce the 
incidence of minor cardiac marker elevation in 192 patients 
undergoing elective coronary stenting [63]. Nicorandil 
treatment reduced the incidence of elevation of cardiac 
markers and decreased the levels of such markers in serum 
after PCI with stent implantation. Kuwabara et al. found that 
in 48 patients treated with elective PCI, intracoronary and 
intravenous nicorandil during PCI improved the recovery of 
myocardial fatty acid utilization on evaluation by iodine-
123-beta-methyl-p-iodophenyl-pentadecanoic acid single 
photon emission computed tomography (I-123 BMIPP 
SPECT), and that this improvement was related to better left 
ventricular systolic function [64]. Iwasaki et al. showed that 
preventive effect on the incidence of slow or no reflow dur-
ing rotational atherectomy was much more seen in patients 
treated with intracoronary nicorandil, compared with vera-
pamil [65].  
 Ito  et al. performed a prospective, single-center study 
including 81 patients with a first anterior AMI who received 
successful PCI and showed effectiveness of intravenous ni-
corandil (6 mg for 24 hours after bolus injection at a dose of 
4 mg) on preventing no-reflow phenomenon microvascular 
function as assessed by intracoronary myocardial contrast 
echocardiography [66]. We reported that the addition of 12 
mg of nicorandil intravenously just before direct PCI accel-
erated ST-segment resolution and improved epicardial flow 
in patients with ST-elevation AMI [67]. 
  Nicorandil dose-dependently increases coronary artery 
blood flow and improves other physiological parameters 
[68], although administration of it, particularly in intracoro-
nary fashion, may induce ventricular arrhythmia [69]. Fur-
ther study is thus needed to determine optimal methods of 
administration and doses of this agent.  
  Diazoxide is also known as an ATP-sensitive potassium 
channel opener. Although experimental studies have shown 
cardioprotective effects of diazoxide, there are limited clini-
cal data in PCI cases.  
Beta-Blockers  
 Beta-blocker  therapy in patients with ischemic heart dis-
ease has been widely reported. Some studies examined 
whether beta-blocker reduced clinical complications in pa-
tients treated with PCI. Some experimental studies have 
shown that intravenous administration of beta-blockers prior 
to coronary artery occlusion favorably reduced electrocar-
diographic and enzymatic parameters [70-72]. 
 Sharma  et al. performed a prospective observational but 
non-randomized study including 1675 consecutive patients 
undergoing PCI, and showed that prior administration of 
beta-blockers before PCI had a cardioprotective effect in 228 Current Cardiology Reviews, 2008, Vol. 4, No. 3 Ishii et al. 
limiting CK-MB release after PCI [73]. On the other hand, 
Ellis et al. reported that there appeared to be no relationship 
between prior beta-blockers use and rise in CK-MB in a 
large and consecutive cohort of 6200 patients undergoing 
PCI [74]. There were important differences between these 
two studies in the statistical methods used to adjust differ-
ences between patients treated with or without beta-blockers. 
However, neither was a randomized study with assignment 
of beta-blockers or placebo to patients.  
  A recent double-blind clinical trial showed that the intra-
coronary administration of propranolol (15 Gg/kg), selec-
tively delivered before first balloon inflation via an intra-
coronary catheter with the tip distal to the coronary lesion, 
significantly reduced the incidence of CK-MB elevation and 
troponin-T elevation after PCI and improve short-term clini-
cal outcomes, compared to placebo [75]. Further study is 
needed to assess the efficacy of beta-blockers in the preven-
tion of myocardial injury.  
ANGIOTENSIN CONVERTING ENZYME INHIBI-
TORS 
  Treatment with angiotensin converting enzyme (ACE) 
inhibitors induces accumulation of bradykinin, reduces 
plasma angiotensin II levels and decreases plasma plasmino-
gen activator inhibitor-1 (PAI-1), a risk factor for myocardial 
infarction [76,77]. These mechanisms are expected to be 
potentially beneficial in patients undergoing PCI. Particu-
larly increasing bradykinin has been experimentally found to 
trigger preconditioning effects experimentally [78]. 
  Recently, it has been reported that enalaprilat increased 
coronary blood flow, and that pretreatment with enalaprilat 
resulted in less ST-segment shift and less chest pain during 
the first balloon inflation in a prospective randomized study 
including 22 patients undergoing elective PCI [79].  
3-hydroxy-3-methylglutaryl co-enzyme A (HMG-CoA) 
Reductase Inhibitors: Statins 
  3-hydroxy-3-methylglutaryl co-enzyme A (HMG-CoA) 
reductase inhibitors (statins) are widely used for treatment 
with hypercholesterolemia and/or coronary artery disease 
[80,81]. It is well known that statins have non-lipid-lowering 
pleiotropic effects including anti-thrombotic effects, im-
provement of vascular endothelial function, and reduction of 
oxidative stress and inflammation [82,83].  
  In nonrandomized observational studies, preoperative 
treatment with statins before elective PCI was associated 
with lower levels of periprocedural CK and CK-MB eleva-
tion [84,85]. Furthermore, randomized trials have indicated 
that statin administration before elective PCI reduces the rate 
of myocardial injury after PCI. In the Atorvastatin for   
Reduction of Myocardial Damage during Angioplasty 
(ARMYDA) study, 153 patients scheduled for elective PCI 
were randomized to receive atorvastatin (40 mg/day) or pla-
cebo 7 days before the procedure [86]. Atorvastatin treat-
ment significantly reduced post-procedural release of several 
markers of myocardial damage, including myoglobin, tro-
ponin I, and CK-MB, compared with the control. Briguori et
al. investigated whether pre-procedural statin administration 
started at least 3 days before elective PCI was effective in 
preventing elevation of myocardial injury after the procedure 
and found that the incidence of CK-MB elevation >5 times 
the upper limit of normal was approximately 50% lower in 
patients treated with pre-procedural statin administration 
[87]. 
  In AMI cases, we recently reported that ST segment reso-
lution >50% on electrocardiography after direct PCI was 
much more observed in patients receiving chronic statin 
treatment before the onset of AMI than in patients without 
statin and that patients treated with statins had a lower peak 
CK levels [88]. Iwakura et al. demonstrated the effectiveness 
of chronic statin pretreatment before AMI in decreasing the 
incidence of the no-reflow phenomenon as assessed by intra-
coronary myocardial contrast echocardiography [89]. 
  Many trials have demonstrated decreases in the incidence 
of myocardial injury after PCI for coronary artery disease in 
patients treated with pre-procedural statins. However, be-
cause these trials consisted of small study samples, larger 
multi-center studies are warranted to corroborate their find-
ings. 
CONCLUSIONS 
  From various mechanisms, pharmacological intervention 
increases coronary blood flow, suppresses myocardial dam-
age, and prevents complications during and after PCI proce-
dures.  
  PCI may induce thromboembolism and/or atheroem-
bolism in the distal coronary bed. The effect of treatment 
with glycoprotein IIb/IIIa inhibitors, bivalirudin, and thieno-
pyridine compounds is thought to block platelet aggregation 
and thus better prevention of procedural thrombus formation. 
Pre-treatment with statins may prevent microvascular plug-
ging due to atheroembolism. PCI may also induce microvas-
cular spasms and/or edema. For these mechanisms, adeno-
sine, nitric oxide, and nicorandil play key roles. Cardiopro-
tective effects mimicking preconditioning effects may de-
crease myocardial injury. From this point, adenosine, ATP-
sensitive potassium channel openers, and ACE inhibitors 
may be useful. It is also important that oxygen free-radical 
production is prevented and endothelial functions are pre-
served by some medications. The ability of pharmacological 
treatment to prevent peri-, and post-procedural myocardial 
injury when added to PCI, thus has important therapeutic 
implications. 
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